1. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

    Cancer 121(6):806 (2015) PMID 25355050 PMCID PMC4352128

    Advances in clinical medicine require effective translational research. Ideally, this research will be performed by multidisciplinary teams that include both physicians and basic scientists. However, the current system does not appropriately train either physicians or basic scientists for these ...
  2. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?

    Cancer 121(6):806 (2015) PMID 25355050 PMCID PMC4352128

    Advances in clinical medicine require effective translational research. Ideally, this research will be performed by multidisciplinary teams that include both physicians and basic scientists. However, the current system does not appropriately train either physicians or basic scientists for these ...
  3. Clinically relevant microRNAs in ovarian cancer.

    Molecular Cancer Research 13(3):393 (2015) PMID 25304686 PMCID PMC4369176

    microRNAs (miRNAs/miRs) belong to a class of small noncoding RNAs that can negatively regulate messenger RNA (mRNA) expression of target genes. miRNAs are involved in multiple aspects of ovarian cancer cell dysfunction and the phenotype of ovarian cancer cells can be modified by targeting miRNA ...
  4. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.

    Cancer Prevention Research 8(1):37 (2015) PMID 25388014

    Point-of-care (POC) diagnostic platforms have the potential to enable low-cost, large-scale screening. As no single biomarker is shed by all ovarian cancers, multiplexed biomarker panels promise improved sensitivity and specificity to address the unmet need for early detection of ovarian cancer....
  5. A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care.

    Cancer Prevention Research 8(1):37 (2015) PMID 25388014

    Point-of-care (POC) diagnostic platforms have the potential to enable low-cost, large-scale screening. As no single biomarker is shed by all ovarian cancers, multiplexed biomarker panels promise improved sensitivity and specificity to address the unmet need for early detection of ovarian cancer....
  6. A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care.

    Cancer Prevention Research 8(1):37 (2015) PMID 25388014

    Point-of-care (POC) diagnostic platforms have the potential to enable low-cost, large-scale screening. As no single biomarker is shed by all ovarian cancers, multiplexed biomarker panels promise improved sensitivity and specificity to address the unmet need for early detection of ovarian cancer....
  7. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.

    Cancer Prevention Research 8(1):37 (2015) PMID 25388014 PMCID PMC4465398

    Point-of-care (POC) diagnostic platforms have the potential to enable low-cost, large-scale screening. As no single biomarker is shed by all ovarian cancers, multiplexed biomarker panels promise improved sensitivity and specificity to address the unmet need for early detection of ovarian cancer....
  8. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.

    PLoS ONE 10(7):e0131833 (2015) PMID 26146988 PMCID PMC4492679

    Cyclin-dependent kinase 5 (CDK5) is a cytoplasmic serine/ threonine kinase. Knockdown of CDK5 enhances paclitaxel sensitivity in human ovarian cancer cells. This study explores the mechanisms by which CDK5 regulates paclitaxel sensitivity in human ovarian cancers. Multiple ovarian cancer cell li...
  9. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.

    Clinical Cancer Research 20(22):5708 (2014) PMID 24833662 PMCID PMC4233015

    To activate and propagate populations of γδ T cells expressing polyclonal repertoire of γ and δ T-cell receptor (TCR) chains for adoptive immunotherapy of cancer, which has yet to be achieved. Clinical-grade artificial antigen-presenting cells (aAPC) derived from K562 tumor cells were used as ir...
  10. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.

    Clinical Cancer Research 20(22):5708 (2014) PMID 24833662 PMCID PMC4233015

    To activate and propagate populations of γδ T cells expressing polyclonal repertoire of γ and δ T-cell receptor (TCR) chains for adoptive immunotherapy of cancer, which has yet to be achieved. Clinical-grade artificial antigen-presenting cells (aAPC) derived from K562 tumor cells were used as ir...
  11. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.

    Clinical Cancer Research 20(22):5708 (2014) PMID 24833662 PMCID PMC4233015

    To activate and propagate populations of γδ T cells expressing polyclonal repertoire of γ and δ T-cell receptor (TCR) chains for adoptive immunotherapy of cancer, which has yet to be achieved. Clinical-grade artificial antigen-presenting cells (aAPC) derived from K562 tumor cells were used as ir...
  12. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.

    Autophagy 10(6):1071 (2014) PMID 24879154 PMCID PMC4091169

    DIRAS3 is an imprinted tumor suppressor gene that is downregulated in 60% of human ovarian cancers. Re-expression of DIRAS3 at physiological levels inhibits proliferation, decreases motility, induces autophagy, and regulates tumor dormancy. Functional inhibition of autophagy with choroquine in d...
  13. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells.

    Autophagy 10(6):1071 (2014) PMID 24879154 PMCID PMC4091169

    DIRAS3 is an imprinted tumor suppressor gene that is downregulated in 60% of human ovarian cancers. Re-expression of DIRAS3 at physiological levels inhibits proliferation, decreases motility, induces autophagy, and regulates tumor dormancy. Functional inhibition of autophagy with choroquine in d...
  14. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening.

    American Journal of Obstetrics and Gynecology 210(3):257.e1 (2014) PMID 24246524 PMCID PMC4001707

    We evaluated baseline knowledge of ovarian cancer risk and perceptions toward ovarian cancer screening (OCS) by initiating the normal risk ovarian screening study. Average-risk, postmenopausal women were enrolled between 2001 and 2011 as they entered the normal risk ovarian screening study. Part...
  15. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening.

    American Journal of Obstetrics and Gynecology 210(3):257.e1 (2014) PMID 24246524 PMCID PMC4001707

    We evaluated baseline knowledge of ovarian cancer risk and perceptions toward ovarian cancer screening (OCS) by initiating the normal risk ovarian screening study. Average-risk, postmenopausal women were enrolled between 2001 and 2011 as they entered the normal risk ovarian screening study. Part...
  16. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening

    American Journal of Obstetrics and Gynecology 210(3):257.e1 (2014)

    Objective We evaluated baseline knowledge of ovarian cancer risk and perceptions toward ovarian cancer screening (OCS) by initiating the normal risk ovarian screening study.
  17. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening.

    American Journal of Obstetrics and Gynecology 210(3):257.e1 (2014) PMID 24246524 PMCID PMC4001707

    We evaluated baseline knowledge of ovarian cancer risk and perceptions toward ovarian cancer screening (OCS) by initiating the normal risk ovarian screening study. Average-risk, postmenopausal women were enrolled between 2001 and 2011 as they entered the normal risk ovarian screening study. Part...
  18. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

    Epigenetics 8(12):1330 (2013) PMID 24135786 PMCID PMC3933493

    The initiation of angiogenesis can mark the transition from tumor dormancy to active growth and recurrence. Mechanisms that regulate recurrence in human cancers are poorly understood, in part because of the absence of relevant models. The induction of ARHI (DIRAS3) induces dormancy and autophagy...
  19. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

    Epigenetics 8(12):1330 (2013) PMID 24135786 PMCID PMC3933493

    The initiation of angiogenesis can mark the transition from tumor dormancy to active growth and recurrence. Mechanisms that regulate recurrence in human cancers are poorly understood, in part because of the absence of relevant models. The induction of ARHI (DIRAS3) induces dormancy and autophagy...
  20. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.

    Epigenetics 8(12):1330 (2013) PMID 24135786 PMCID PMC3933493

    The initiation of angiogenesis can mark the transition from tumor dormancy to active growth and recurrence. Mechanisms that regulate recurrence in human cancers are poorly understood, in part because of the absence of relevant models. The induction of ARHI (DIRAS3) induces dormancy and autophagy...